CureVac’s mRNA Covid vaccine flunks clinical trial
Shares of German biotech plunge after interim results show jab is only 47% effective
Full Article
CureVac’s mRNA Covid vaccine flunks clinical trial
FT.com
0 shares
1 views
You might like
Related news coverage
Scientists Are Testing an mRNA Vaccine for Brain Cancer
Veuer
Researchers at the University of Florida have announced encouraging results from a clinical trial of an mRNA vaccine for brain..
-
Businessinsider.co.za | German biotech CureVac's stock plunges 50% after its Covid-19 vaccine candidate failed clinical trial
News24
-
German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trial
Business Insider
-
Interim trial data shows low effectiveness for CureVac shot
SeattlePI.com
-
CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial
NYTimes.com
Advertisement
More coverage
Patent Monopolies And Inequality – Analysis
In recent weeks there have been several articles noting the enormous wealth that a small number of people have made off of the..
Eurasia Review
CureVac shares tank 50% after preliminary data shows Covid vaccine is only 47% effective
The late-stage clinical trial found high prevalence of virus variants.
Upworthy